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Aims After percutaneous coronary intervention (PCI) in patients with atrial fibrillation, safety and efficacy with dabigatran
dual therapy were evaluated in pre-specified subgroups of patients undergoing PCI due to acute coronary syn-
drome (ACS) or elective PCI, and those receiving ticagrelor or clopidogrel treatment.
...................................................................................................................................................................................................
Methods
and results
In the RE-DUAL PCI trial, 2725 patients were randomized to dabigatran 110 mg or 150 mg with P2Y12 inhibitor,
or warfarin with P2Y12 inhibitor and aspirin. Mean follow-up was 14 months, 50.5% had ACS, and 12% received
ticagrelor. The risk of the primary endpoint, major or clinically relevant non-major bleeding event, was reduced
with both dabigatran dual therapies vs. warfarin triple therapy in patients with ACS [hazard ratio (95% confidence
interval), 0.47 (0.35–0.63) for 110 mg and 0.67 (0.50–0.90) for 150 mg]; elective PCI [0.57 (0.43–0.76) for 110 mg
and 0.76 (0.56–1.03) for 150 mg]; receiving ticagrelor [0.46 (0.28–0.76) for 110 mg and 0.59 (0.34–1.04) for
150 mg]; or clopidogrel [0.51 (0.41–0.64) for 110 mg and 0.73 (0.58–0.91) for 150 mg], all interaction P-values
>0.10. Overall, dabigatran dual therapy was comparable to warfarin triple therapy for the composite endpoint of
death, myocardial infarction, stroke, systemic embolism, or unplanned revascularization, with minor variations
across the subgroups, all interaction P-values >0.10.
...................................................................................................................................................................................................
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Conclusion The benefits of both dabigatran 110 mg and 150 mg dual therapy compared with warfarin triple therapy in reducing
bleeding risks were consistent across subgroups of patients with or without ACS, and patients treated with ticagre-
lor or clopidogrel.
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Introduction
Recent estimates suggest an atrial fibrillation (AF) prevalence of3%
in adults above the age of 20 years.1,2 Coronary artery disease com-
monly co-exists with AF and at least 5% of unselected patients under-
going percutaneous coronary interventions (PCIs) have AF, which
poses an antithrombotic treatment dilemma.3,4 Oral anticoagulation
for prevention of stroke is indicated in the majority of patients with
AF,5,6 whereas dual antiplatelet therapy with a P2Y12 inhibitor plus
aspirin is indicated for patients undergoing PCI with stent implant-
ation and/or after an acute coronary syndrome (ACS).7
Contemporary guidelines5–9 recommend a short period of triple
therapy with both oral anticoagulation and dual antiplatelet therapy
with aspirin and clopidogrel, although these triple regimens are inevit-
ably associated with higher rates of major bleeding. The use of the
newer P2Y12 inhibitors prasugrel or ticagrelor as part of triple ther-
apy is discouraged,6,7,9,10 given the lack of evidence of the safety of
those drugs in combination with oral anticoagulation therapy.
Results of observational studies, randomized trials, and meta-
analyses suggest that dual antithrombotic treatment, i.e. an oral anti-
coagulant—either a non-vitamin K antagonist oral anticoagulant
(NOAC) or a vitamin K antagonist (VKA)—in combination with one
antiplatelet agent, most commonly a P2Y12 inhibitor, reduces bleed-
ing events without increased risk of thromboembolic events com-
pared with triple treatment.11–15 More recently, the RE-DUAL PCI
(Randomized Evaluation of DUAL Antithrombotic Therapy With
Dabigatran vs. Triple Therapy With Warfarin In Patients With
Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary
Intervention) trial showed that the risk of major or clinically relevant
non-major bleeding events was reduced by 48% with dabigatran
110 mg dual therapy without aspirin, and by 28% with dabigatran
150 mg dual therapy without aspirin, respectively, with non-inferiority
for overall thromboembolic events with dabigatran (both doses com-
bined) dual therapy compared with warfarin triple therapy with both
aspirin and a P2Y12 inhibitor.16,17 In the present analysis, we evaluated
the safety and efficacy of dabigatran dual vs. warfarin triple therapy in
the pre-specified patient subgroups with PCI due to ACS or under-
going elective PCI, and those treated with ticagrelor or clopidogrel.
Methods
The RE-DUAL PCI trial was a prospective, randomized, open-label study
comparing the safety and efficacy of dabigatran dual antithrombotic ther-
apy vs. warfarin triple therapy. The detailed design and primary results of
RE-DUAL PCI have been published (RE-DUAL PCI ClinicalTrials.gov
number, NCT02164864).16,17 Men and women who were at least
18 years of age were eligible for inclusion if they had non-valvular AF and
had been successfully treated with PCI with a bare-metal or drug-eluting
stent within the prior 120 h. Non-valvular AF could be paroxysmal, per-
sistent, or permanent, but not secondary to a reversible disorder unless
long-term treatment with an oral anticoagulant was anticipated. Patients
could be either treatment-naı̈ve or receiving an oral anticoagulant prior
to PCI. The indication for PCI could be either an ACS or stable coronary
artery disease. Exclusion criteria included patients with bioprosthetic or
mechanical heart valves, severe renal insufficiency (creatinine clearance
<30 mL/min), or other major comorbidities.
Patients were randomized to dabigatran 110 mg twice daily plus either
clopidogrel or ticagrelor (dabigatran 110 dual therapy); dabigatran
150 mg twice daily plus either clopidogrel or ticagrelor (dabigatran 150
dual therapy); or warfarin plus either clopidogrel or ticagrelor, and aspirin
at a daily dose of 100 mg or less (warfarin triple-therapy) in a 1:1:1 ratio.
In the warfarin arm, aspirin was discontinued after 1 month in patients
implanted with a bare-metal stent, and after 3 months in patients
implanted with a drug-eluting stent. Outside the USA, patients aged
>_80 years (>_70 years in Japan) were only randomized to the 110-mg
dabigatran dose vs. warfarin in a 1:1 ratio. All patients received either clo-
pidogrel 75 mg daily or ticagrelor 90 mg twice daily for at least 12 months
following randomization, with the choice of agent at the discretion of the
investigator, but the protocol specified that this decision was to be taken
prior to randomization. Prasugrel was not allowed in the study. The dose
of warfarin was adjusted to ensure the patient’s international normalized
ratio was in the range of 2.0–3.0.
The present subgroup analyses of patients with or without ACS at
index PCI and patients treated with ticagrelor or clopidogrel were pre-
specified. The RE-DUAL PCI trial primary endpoint was time to first
International Society on Thrombosis and Haemostasis (ISTH) major18 or
clinically relevant non-major19 bleeding event. Further safety endpoints
included major bleeding events according to ISTH18 and Thrombolysis in
Myocardial Infarction (TIMI)20 definitions; and efficacy outcomes including
the composite of death or thromboembolic events (myocardial infarc-
tion, stroke, or systemic embolism), or unplanned revascularization (PCI/
coronary artery bypass graft), myocardial infarction and all-cause death.
All clinical endpoints were adjudicated by an independent committee
blinded to treatment assignment.
Statistics
Patients were grouped according to the index PCI indication, i.e. patients
either undergoing PCI due to ACS, or undergoing elective PCI due to sta-
ble angina and/or positive stress test, staged procedure, or other, and
according to the P2Y12 inhibitor use at baseline. The latter subgroup ana-
lysis was performed by grouping the patients uniquely into patients who
received ticagrelor at baseline (further referred ‘ticagrelor’), which
included 58 patients who took both ticagrelor and clopidogrel on the day
of randomization (i.e. at baseline), and patients who did not receive tica-
grelor at baseline (further referred ‘clopidogrel’), which included 93
patients who received neither ticagrelor nor clopidogrel at baseline.
The clinical characteristics were summarized descriptively by ACS or
elective PCI at index event as well as by treatment with ticagrelor or
1554 J. Oldgren et al.
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clopidogrel at baseline, with P-values using the t-test for continuous varia-
bles and the v2 test for categorical variables. For the comparison of treat-
ment groups within the index PCI indication and P2Y12 inhibitor
subgroups, stratified Cox proportional hazards regression models including
age group as a stratifying factor [non-elderly or elderly (<70 years or
>_70 years old in Japan and <80 years or >_80 years old elsewhere)] and
treatment (dabigatran 110 dual therapy vs. warfarin triple therapy) as ex-
planatory factor were applied. For the dabigatran 150 dual therapy vs. war-
farin triple therapy comparison, unstratified models were applied.
A corresponding triple-therapy warfarin group that included only patients
eligible for dabigatran 150 dual therapy (i.e. not elderly patients outside the
USA) was used for this comparison. Hazard ratios (HRs) and two-sided
95% Wald confidence intervals (CIs) for HRs resulting from Cox propor-
tional hazard models were calculated within the index PCI indication and
P2Y12 inhibitor subgroups. Exploratory treatment by subgroup interaction
P-values resulting from Cox proportional hazard regression models strati-
fied by age for dabigatran 110 dual therapy vs. warfarin triple therapy and
unstratified for dabigatran 150 dual therapy vs. warfarin triple therapy,
respectively, were provided. Additionally, the risk of the primary end-
point (ISTH major or clinically relevant non-major bleeding events)
and of the composite efficacy endpoint of death, thromboembolic
events, or unplanned revascularization, respectively, was compared
between ticagrelor- and clopidogrel-treated patients as well as be-
tween patients with ACS and elective PCI with a multivariable
adjusted treatment-independent and stratified (non-elderly or elder-
ly) Cox proportional hazard regression model. For the bleeding end-
point, the Cox model was adjusted for bleeding risk factors, i.e. age,
creatinine clearance, previous stroke, prior major bleeding events or
bleeding predisposition, diabetes, and ACS or ticagrelor use, respect-
ively. For the composite efficacy endpoint, adjustment was performed
for risk factors of death and thromboembolic events, i.e. age, creatin-
ine clearance, prior myocardial infarction, previous stroke, diabetes,
multi-vessel disease, and ACS or ticagrelor use, respectively. HRs and
two-sided 95% CIs from this Cox model were provided.
Results
Baseline characteristics
Baseline characteristics of the 2725 patients enrolled in RE-DUAL PCI
are presented by ACS or elective PCI at index event in Table 1, and by
treatment with ticagrelor or clopidogrel are presented in Table 2.
The index indication for PCI was ACS in 1375 (50.5%) patients;
within the treatment groups, the index indication for PCI was ACS
for 509 (51.9%) of the 981 patients randomized to dabigatran 110 mg
dual therapy, 391 (51.2%) of the 763 patients randomized to dabiga-
tran 150 mg dual therapy, 475 (48.4%) of the 981 patients random-
ized to warfarin triple therapy, and 369 (48.3%) of the 764 patients
randomized to warfarin triple therapy excluding elderly patients out-
side the USA. Patients in the ACS and elective PCI subgroups were
of similar age but a lower proportion of ACS patients were males
(73.5% vs. 78.5%). The most common type of ACS was non-ST-
elevation myocardial infarction (42.3%), followed by unstable an-
gina (33.6%) and ST-elevation myocardial infarction (22.2%). The
proportions of oral anticoagulant treatment-naı̈ve patients at
baseline, defined as having <14 days of consecutive oral anticoagu-
lant treatment, were 74.3% in the ACS subgroup and 57.4% in the
elective PCI group. Clinical and procedural complexity factors21
and prior myocardial infarction were more common in the ACS
group, Table 1. Drug-eluting stents were predominantly used in all
patients but slightly more commonly in the elective PCI group
than the ACS group.
Ticagrelor was chosen (by the investigators) as the P2Y12 inhibitor in
327 (12.0%) patients; within each treatment group, ticagrelor was
chosen in 132 (13.5%) of the 981 patients randomized to dabigatran
110 mg dual therapy, in 104 (13.6%) of those 763 patients randomized
to dabigatran 150 mg dual therapy, in 91 (9.3%) of those 981 patients
randomized to warfarin triple therapy, and in 73 (9.6%) of those 764
patients randomized to warfarin triple therapy excluding elderly patients
outside the USA. Mean age was 69.7 years and 70.9 years in the ticagre-
lor- and clopidogrel-treated patients. Type of AF was paroxysmal in
56.6% and 48.6%, and permanent in 26.9% and 33.4%, of patients
treated with ticagrelor or clopidogrel, respectively. The proportions of
patients with prior stroke were 6.1% in the ticagrelor group and 8.6% in
the clopidogrel group, and 76.1% and 64.5% were oral anticoagulant
treatment-naı̈ve, respectively. In the ticagrelor group, 73.4% of the
patients had an ACS at index event, and 47.3% had ACS at index in the
clopidogrel group. Mean CHA2DS2-VASc and modified HAS-BLED
scores were slightly higher in patients treated with clopidogrel, but clin-
ical complexity factors, and the combination of clinical and procedural
factors, were more common in those treated with ticagrelor, Table 2.
Bleeding events
The overall incidence (independent of study treatment, i.e. dabigatran
or warfarin) of the first ISTH major or clinically relevant non-major
bleeding event was 20.9% in patients with PCI due to ACS, and 20.9%
in those who had undergone elective PCI; multivariable adjusted
treatment independent HR 0.97 with a two-sided 95% CI of 0.81–
1.15. The risk of experiencing ISTH major or clinically relevant non-
major bleeding was reduced with dabigatran dual therapy vs. warfarin
triple therapy in patients with ACS and undergoing elective PCI,
Figure 1. Compared with warfarin triple therapy, the risks of experi-
encing ISTH major bleeding events alone and TIMI major bleeding
events were also consistently reduced with both dabigatran 110 mg
dual therapy and dabigatran 150 mg dual therapy for patients with
ACS and undergoing elective PCI. All interaction P-values were non-
significant; thus no interaction between study treatment and index
PCI indication could be detected.
In the group of patients treated with ticagrelor, the study treat-
ment-independent incidence of the first ISTH major or clinically rele-
vant non-major bleeding event was 26.3%, and in those treated with
clopidogrel 20.1%; multivariable adjusted HR 1.35, 95% CI 1.05–1.72.
Across the subgroups of patients with ticagrelor or clopidogrel, the
risks of experiencing the primary outcome of ISTH major or clinically
relevant non-major bleeding, as well as ISTH major bleeding events
alone, and TIMI major bleeding events, were consistently reduced
with dabigatran 110 mg dual therapy and dabigatran 150 mg dual
therapy vs. warfarin triple therapy, Figure 2 and Supplementary mater-
ial online, Figure S1. All interaction P-values were non-significant.
Death, thromboembolic events, or
unplanned revascularization
The study treatment-independent incidence of death, thrombo-
embolic events, or unplanned revascularization was 14.8% in patients
with ACS and 12.4% in patients undergoing elective PCI; multivari-
able adjusted HR 1.13, 95% CI 0.91–1.41. The study treatment
Dabigatran dual therapy with ticagrelor or clopidogrel after PCI 1555
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planned revascularization was 18.7% in those treated with ticagrelor
and 12.9% in those treated with clopidogrel; multivariable adjusted
HR 1.34, 95% CI 1.00–1.82.
Minor variations were observed for the composite endpoint of
death, thromboembolic events, or unplanned revascularization, for
dabigatran 110 mg or 150 mg dual therapy vs. warfarin triple across
subgroups of ACS and elective PCI, Figure 3, and those treated with
ticagrelor or clopidogrel, Figure 4 and Supplementary material online,
Figure S2, but all interaction P-values were non-significant. Numerical
differences in the composite of death or thromboembolic events, and
for the individual thromboembolic endpoints stroke and all-cause mor-
tality, respectively, were also observed for dabigatran 110 mg or
150 mg dual therapy vs. warfarin triple therapy across subgroups of
ACS and elective PCI, Figure 3, but all interaction P-values were non-
significant. In the ACS subgroup, numerically higher rates of myocardial
infarction and stent thrombosis were observed with dabigatran 110 mg
dual therapy vs. warfarin triple therapy, interaction P = 0.20 and 0.07,
respectively. Numerical differences in the composite of death or
thromboembolic events and the individual thromboembolic endpoints
were also observed for those patients treated with ticagrelor or clopi-
dogrel, Figure 4, but all interaction P-values were non-significant.
Discussion
The benefits of both dabigatran 110 mg and 150 mg dual therapy,
with substantial reduction in major and clinically relevant non-major
....................................................................................................................................................................................................................
Table 1 Baseline characteristics by indication for percutaneous coronary intervention
ACS (N 5 1375) Elective PCIa (N 5 1349) P-value
Age (years), mean (SD) 70.9 (9.1) 70.6 (8.1) 0.3406
Male, n (%) 1010 (73.5) 1059 (78.5) 0.0021
Type of atrial fibrillation, n (%) 0.1047
Paroxysmal 708 (51.5) 643 (47.7)
Persistent 229 (16.7) 255 (18.9)
Permanent 437 (31.8) 451 (33.4)
Type of ACS, n (%)b NA
Unstable angina 462 (33.6) NA
STEMI 305 (22.2) NA
NSTEMI 582 (42.3) NA
Diabetes, n (%) 492 (35.8) 501 (37.1) 0.4620
Prior stroke, n (%) 106 (7.7) 120 (8.9) 0.2617
Prior myocardial infarction, n (%) 390 (28.4) 309 (22.9) 0.0011
Creatinine clearance (mL/min), mean (SD)c 77.2 (29.9) 78.8 (29.6) 0.1832
CHA2DS2-VASc, mean (SD) 3.6 (1.6) 3.6 (1.5) 0.3887
Modified HAS-BLED, mean (SD) 2.7 (0.7) 2.7 (0.7) 0.1105
OAC treatment at baseline, n (%) <0.0001
Long-term 354 (25.7) 574 (42.6)
Treatment naı̈ved 1021 (74.3) 775 (57.4)
Complexity factors, n (%)e <0.0001
No clinical/procedural factors 0 1007 (74.6)
Clinical complexity factors only 1114 (81.0) 60 (4.4)
Procedural complexity factors only 0 270 (20.0)
Both clinical and procedural factors 261 (19.0) 12 (0.9)
Type of stent,f n (%) 0.0006
DES only 1099 (79.9) 1152 (85.4)
BMS only 239 (17.4) 165 (12.2)
DES and BMS, or other 33 (2.4) 29 (2.1)
Information on indication for PCI was missing for one patient. Statistics: using the t-test for continuous variables and the v2 test for categorical variables.
ACS, acute coronary syndrome; BMS, bare-metal stent; DES, drug-eluting stent; NA, not applicable; NSTEMI, non-ST-elevation myocardial infarction; OAC, oral anticoagulant;
PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.
aElective PCI includes stable angina and/or positive stress test, staged procedure, or other indication.
bData missing for 26 patients.
cMean creatinine clearance missing at baseline for 138 patients in ACS and 93 patients in elective PCI group.
dLess than 14 days’ consecutive OAC treatment.
eClinical complexity factors considered are acute coronary syndrome, acute ST-elevation myocardial infarction, renal insufficiency/failure, and left ventricular ejection fraction
<30%. Procedural (including lesion) complexity factors are >2 vessels stented, in-stent restenosis of a drug-eluting stent, prior brachytherapy, unprotected left main stenting,
>2 lesions per vessel, lesion length >_30 mm, bifurcation lesion with side branch >_2.5 mm, vein bypass graft, and thrombus-containing lesion (from Yeh et al.21).
fType of stent missing for four patients in ACS and three patients in elective PCI group.
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bleeding events, and ISTH and TIMI major bleeding events, compared
with warfarin triple therapy were consistent across the pre-specified
subgroups of patients with ACS or elective PCI and in those treated
with the P2Y12 inhibitors ticagrelor or clopidogrel.
At least 5% of unselected patients undergoing PCI have AF,4 and
15% of AF patients have a history of myocardial infarction.22,23 In
patients hospitalized for an ACS, an AF incidence up to 21% has been
reported, and this combination is associated with worse outcome
including higher risk for stroke, myocardial infarction, and death.24,25
Therefore, patients with AF undergoing PCI with stent implantation
are most often at sufficient increased risk for thromboembolic com-
plications warranting long-term oral anticoagulation therapy, irre-
spective of the indication for PCI being ACS or elective PCI.
However, the choice of antiplatelet drugs and treatment durations
may differ after an ACS or an elective PCI.
In the RE-DUAL PCI trial, the equally sized subgroups of patients
with ACS or elective PCI as the index event had similar baseline char-
acteristics, mean CHA2DS2-VASc and modified HAS-BLED scores,
....................................................................................................................................................................................................................
Table 2 Baseline characteristics by treatment with ticagrelor or clopidogrel
Ticagrelora (N 5 327) Clopidogrelb (N 5 2398) P-value
Age (years), mean (SD) 69.7 (9.6) 70.9 (8.5) 0.0323
Male, n (%) 253 (77.4) 1817 (75.8) 0.5257
Type of atrial fibrillation, n (%) 0.0197
Paroxysmal 185 (56.6) 1166 (48.6)
Persistent 53 (16.2) 431 (18.0)
Permanent 88 (26.9) 800 (33.4)
Indication for PCI, n (%) <0.0001
Elective PCIc 87 (26.6) 1262 (52.6)
ACS 240 (73.4) 1135 (47.3) <0.0001
Type of ACS, n (%)d
Unstable angina 54 (22.5) 408 (35.9)
NSTEMI 105 (43.8) 477 (42.0)
STEMI 79 (32.9) 226 (19.9)
Diabetes, n (%) 123 (37.6) 870 (36.3) 0.6419
Prior stroke, n (%) 20 (6.1) 206 (8.6) 0.1275
Prior myocardial infarction, n (%) 91 (27.8) 608 (25.4) 0.3365
Creatinine clearance (mL/min), mean (SD) 80.5 (32.2) 77.7 (29.4) 0.1507
CHA2DS2-VASc, mean (SD) 3.4 (1.6) 3.6 (1.5) 0.0282
Modified HAS-BLED, mean (SD) 2.6 (0.7) 2.7 (0.7) 0.0057
OAC treatment at baseline, n (%) <0.0001
Long-term 78 (23.9) 851 (35.5)
Treatment naı̈vee 249 (76.1) 1547 (64.5)
Complexity factors, n (%)f <0.0001
No clinical/procedural factors 67 (20.5) 941 (39.2)
Clinical factors only 193 (59.0) 981 (40.9)
Procedural factors only 16 (4.9) 254 (10.6)
Both clinical and procedural factors 51 (15.6) 222 (9.3)
Type of stent, n (%)g 0.1556
DES only 275 (84.1) 1976 (82.4)
BMS only 40 (12.2) 364 (15.2)
DES and BMS, or other 11 (3.4) 51 (2.1)
Statistics: using the t-test for continuous variables and the v2 test for categorical variables.
ACS, acute coronary syndrome; BMS, bare-metal stent; DES, drug-eluting stent; NSTEMI, non-ST-elevation myocardial infarction; OAC, oral anticoagulant; PCI, percutaneous
coronary intervention; STEMI, ST-elevation myocardial infarction.
aFifty-eight patients who received ticagrelor þ clopidogrel are included in the ticagrelor subgroup.
bNinety-three patients who received neither clopidogrel nor ticagrelor are included in the clopidogrel subgroup; data on atrial fibrillation, diabetes, prior stroke, and indication
for PCI were missing for one patient in the clopidogrel group.
cElective PCI includes stable angina and/or positive stress test, staged procedure, or other indication.
dData missing for two patients in the ticagrelor and for 24 patients in the clopidogrel group.
eLess than 14 days’ consecutive OAC treatment.
fClinical complexity factors considered are acute coronary syndrome, acute ST-elevation myocardial infarction, renal insufficiency/failure, and left ventricular ejection fraction
<30%. Procedural (including lesion) complexity factors are >2 vessels stented, in-stent restenosis of a drug-eluting stent, prior brachytherapy, unprotected left main stenting,
>2 lesions per vessel, lesion length >_30 mm, bifurcation lesion with side branch >_2.5 mm, vein bypass graft, and thrombus-containing lesion (from Yeh et al.21).
gType of stent was missing for one patient in the ticagrelor and seven patients in the clopidogrel group.
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Figure 1 Bleeding events by percutaneous coronary intervention indication at index event. aFrom Cox proportional hazard model stratified by
age (elderly vs. non-elderly). bFor the comparison with dabigatran 150 mg dual therapy, elderly patients outside the USA were excluded. cFrom
unstratified Cox proportional hazard model. ACS, acute coronary syndrome; CI, confidence interval; CRNM, clinically relevant non-major; ISTH,
International Society on Thrombosis and Haemostasis; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.
Figure 2 Bleeding events by treatment with ticagrelor or clopidogrel. Fifty-eight patients who received ticagrelorþ clopidogrel are included in the
ticagrelor subgroup; 93 patients who received neither clopidogrel nor ticagrelor are included in the clopidogrel subgroup. The choice of ticagrelor or
clopidogrel was at the discretion of the investigator, these groups are not directly comparable due to allocation bias. aFrom Cox proportional hazard
model stratified by age (elderly vs. non-elderly). bFor the comparison with dabigatran 150 mg dual therapy, elderly patients outside the USA were
excluded. cFrom unstratified Cox proportional hazard model. ACS, acute coronary syndrome; CI, confidence interval; CRNM, clinically relevant
non-major; ISTH, International Society on Thrombosis and Haemostasis; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial
infarction.
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..and primary safety outcome incidences. Both dabigatran dual thera-
pies were associated with substantially reduced risk of bleeding events
compared with warfarin triple therapy without signs of interaction be-
tween study treatment and the indication for PCI (ACS or elective).
The risk of the composite of death, thromboembolic events, or un-
planned revascularization with dabigatran dual therapies seemed com-
parable to warfarin triple therapy in the ACS and elective PCI
subgroups. While there was substantially less bleeding with dabigatran
110 mg dual therapy compared with warfarin triple therapy, numeric-
ally higher risks of myocardial infarction and stent thrombosis were
observed in the ACS population, although the number of events was
small and interaction P-values were non-significant. These differences
should be interpreted with caution as the main RE-DUAL PCI study
was not adequately powered for individual thromboembolic events,
and the results in the present analysis are based on even smaller num-
bers of patients and events within each subgroup. Importantly, both
dabigatran doses in the dual therapy groups have previously been eval-
uated for stroke prevention compared with warfarin. In the pivotal
RE-LY study,26 dabigatran 150 mg was superior to warfarin with a 35%
risk reduction in stroke, whereas dabigatran 110 mg was non-inferior
to warfarin for stroke prevention. Thus, irrespective of ACS or elect-
ive PCI at the index event, dabigatran 150 mg dual therapy is an at-
tractive option after PCI in patients with AF,9 whereas dabigatran
110 mg dual therapy should be considered in very elderly patients and
those at increased bleeding risk.
In the PIONEER-AF PCI trial,13 both dual therapy with rivaroxaban
15 mg once daily and triple therapy with rivaroxaban 2.5 mg twice
daily also reduced clinically relevant bleeding events compared with
Figure 3 Death, thromboembolic events, and unplanned revascularization by percutaneous coronary intervention indication at index event.
aFrom Cox proportional hazard model stratified by age (elderly vs. non-elderly). bFor the comparison with dabigatran 150 mg dual therapy, elderly
patients outside the USA were excluded. cFrom unstratified Cox proportional hazard model. ACS, acute coronary syndrome; CI, confidence interval;
DTE, death or thromboembolic event (myocardial infarction, stroke, or systemic embolism); PCI, percutaneous coronary intervention.
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..VKA triple therapy in patients with AF after PCI. Similar to the pre-
sent trial, the groups of patient with or without ACS at index PCI
intervention were of equal size in PIONEER-AF PCI, and the authors
reported consistent results in the ACS subgroup.
In the RE-DUAL PCI trial, the choice of the P2Y12 inhibitors clopi-
dogrel or ticagrelor was at the discretion of the investigator. The vast
majority of the study patients were treated with clopidogrel, but 12%
of the patients received ticagrelor as part of their antithrombotic
regimen. In the PIONEER-AF PCI trial,13 the choice of P2Y12 inhibi-
tor was likewise at the investigators’ discretion, but only 4.3% of the
patients received ticagrelor and 1.3% received prasugrel (the latter
not allowed in RE-DUAL PCI). In the present study, the majority of
patients treated with ticagrelor (73%) had an ACS at index event, in
line with contemporary guidelines recommending ticagrelor in pref-
erence to clopidogrel on top of aspirin after an ACS episode.7 Not
surprisingly, patients treated with ticagrelor had a higher bleeding risk
than the patients who the physician treated with clopidogrel.
A higher risk of bleeding in patients with ACS treated with ticagrelor
(but not on oral anticoagulants) compared with clopidogrel has also
been reported in the PLATO trial.27
Patients treated with ticagrelor at investigator’s discretion were
also associated with higher risk of the composite of death, thrombo-
embolic events, or unplanned revascularization, of borderline statis-
tical significance, than patients receiving clopidogrel in the present
Figure 4 Death, thromboembolic events, and unplanned revascularization by treatment with ticagrelor or clopidogrel. The choice of ticagrelor or
clopidogrel was at the discretion of the investigator, these groups are not directly comparable due to allocation bias. aFrom Cox proportional hazard
model stratified by age (elderly vs. non-elderly). bFor the comparison with dabigatran 150 mg dual therapy, elderly patients outside the USA were
excluded. cFrom unstratified Cox proportional hazard model. CI, confidence interval; DTE, death or thromboembolic event (myocardial infarction,
stroke, or systemic embolism); HR, hazard ratio; n.d., not done (one treatment group had zero events and HR is not given).
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study. In contrast, ticagrelor was significantly associated with 16%
lower risk for the primary composite outcome of cardiovascular
death, myocardial infarction, or stroke, compared to clopidogrel in
the aforementioned randomized PLATO trial.27 Despite multivari-
able statistical adjustments, our findings may merely reflect that
patients receiving ticagrelor, at the choice of the investigator, were at
higher risk for thromboembolic and bleeding events, e.g. because of
clinical and procedural complexity factors.
Despite the higher bleeding risk observed in patients treated with
ticagrelor, the benefits of both dabigatran 110 mg and 150 mg dual
therapy compared with warfarin triple therapy were consistent
across the ticagrelor and clopidogrel subgroups. In patients with AF
where more intensive platelet inhibition is warranted, e.g. after an
ACS with high risk for new coronary events, or in patients who are
non-responders to clopidogrel and thereby at high risk for thrombo-
embolic events,28 dabigatran dual therapy with ticagrelor might be an
attractive alternative after PCI as recently suggested in a North
American consensus document.10 Notably the trend for higher risk
for myocardial infarction and stent thrombosis in patients treated
with dabigatran 110 mg dual therapy compared with warfarin triple
therapy seemed attenuated in those patients receiving ticagrelor,
with the caveat that this finding is based on a small subgroup of
patients.
Approximately 10% of patients in the warfarin triple therapy group
received ticagrelor in combination with aspirin and warfarin in the
present study. Albeit based on modest numbers, the high bleeding
rates in these patients support current guideline recommendations
to avoid newer P2Y12 inhibitors as part of oral anticoagulant triple
therapy.6,7,9,10 In addition, in previous small observational studies,29–
31 VKA or NOAC triple therapy with ticagrelor or prasugrel have
been associated with up to three times higher risk of bleeding events
compared to triple therapy with clopidogrel.
This report has limitations. Subgroup analyses, albeit pre-
specified, should always be interpreted cautiously as these individ-
ual subgroups were not powered for formal statistical testing of
each individual subgroup, and therefore the CIs were inevitably
wider than in the main study due to the smaller numbers of
patients and events, especially in the relatively small subgroup of
patients receiving ticagrelor. Also, interaction P-values should be
regarded as exploratory. The magnitude of increased bleeding risk
with ticagrelor compared to clopidogrel was somewhat higher in
the present study than in the randomized post-ACS trial comparing
Take home figure The benefits of both dabigatran 110 mg and 150 mg dual therapy compared with warfarin triple therapy in reducing bleeding
risks were consistent across subgroups of patients with or without ACS, and patients treated with ticagrelor or clopidogrel. ACS, acute coronary syn-
drome; ASA, aspirin; CI, confidence interval; ISTH, International Society on Thrombosis and Haemostasis; PCI, percutaneous coronary intervention.
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ticagrelor vs. clopidogrel on top of aspirin but not oral anticoagu-
lant treatment.27 This might imply an incremental bleeding risk with
ticagrelor in combination with oral anticoagulants, also indicated by
small observational studies.29–31 However, this interpretation is lim-
ited by the non-randomized comparisons of P2Y12 inhibitors in
the present study, as well as in the observational studies, and the
small subgroup of patients receiving ticagrelor. Lastly, the assign-
ment of patients to the P2Y12 inhibitor was not randomized but
chosen at the discretion of the investigator, so that residual con-
founding or classification bias cannot be excluded.
Conclusions
In patients with AF who had undergone PCI, the benefits of both
dabigatran 110 mg and 150 mg dual therapy compared with warfarin
triple therapy in reducing bleeding risks were consistent across sub-
groups of patients with or without ACS at index event, and those
treated with ticagrelor or clopidogrel.
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